4 56Mg Donepezil Free Base

證據等級: L5

預測適應症: 0 個

Donepezil 4.56 mg (Free Base): Data Quality Issues Prevent Repurposing Evaluation

⚠️ Note: The standard title format From [Original Indication] to [Predicted New Indication] cannot be applied because this Evidence Pack contains no predicted indications. The root cause is identified below.

One-Sentence Summary

The entry 4.56MG DONEPEZIL FREE BASE appears to refer to a transdermal patch formulation of donepezil, a reversible acetylcholinesterase inhibitor used for Alzheimer's disease. However, the TxGNN model generated no predicted indications for this entry — most likely due to a drug name normalization failure where the dosage value and formulation descriptor were parsed as part of the INN. No Singapore market registrations were found, and a complete repurposing evaluation cannot be produced until the upstream data quality issues are resolved.

Quick Overview

Item	Content
Original Indication	Not recorded in Evidence Pack (donepezil is clinically approved for Alzheimer's disease)
Predicted New Indication	None — TxGNN generated zero predictions for this entry
TxGNN Prediction Score	N/A
Evidence Level	Not applicable
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why Were No Predictions Generated?

The drug identifier submitted to the pipeline — 4.56MG DONEPEZIL FREE BASE — mixes three distinct pieces of information: a dosage quantity (4.56MG), the INN (DONEPEZIL), and a salt/formulation descriptor (FREE BASE). This non-standard composite string is the most probable cause of the TxGNN mapping failure: the pipeline was unable to resolve this entry to the correct DrugBank node, and consequently produced no disease predictions.

Interestingly, the query log (ID 2) records a successful DrugBank lookup with result_count: 1, which suggests the underlying compound was identified at some stage of the pipeline. The predictions were either never requested or were discarded before reaching the output layer. Re-running with the clean INN Donepezil (DrugBank: DB00843) should recover predictions.

Donepezil is a well-characterised compound with a known mechanism of action (reversible inhibition of acetylcholinesterase → increased synaptic acetylcholine → improved cholinergic transmission). Its pharmacological profile has been explored in multiple disease contexts beyond Alzheimer's disease (e.g., vascular dementia, Lewy body dementia, and various neuropsychiatric indications), meaning TxGNN would be expected to generate meaningful candidates once the identifier is corrected.

Singapore Market Information

No HSA registrations were found for the string 4.56MG DONEPEZIL FREE BASE. This is expected: Singapore product registrations are filed under the INN (Donepezil) or specific brand names (e.g., Aricept®, Memac®), not under dosage-qualified strings. A separate query under the correct INN or known brand names is needed to determine actual Singapore market status.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack cannot support a repurposing evaluation in its current form. The drug name is not a valid INN, no TxGNN predictions were generated, and all safety data fields are unresolved. The underlying compound (donepezil) is well-characterised and evaluation-ready — the obstacle is entirely a data pipeline issue.

To proceed, the following is needed:

Normalize the drug name: Strip the dosage (4.56MG) and salt descriptor (FREE BASE) and resubmit as the bare INN Donepezil
Re-run the TxGNN prediction pipeline using the corrected identifier to generate predicted_indications
Retrieve MOA and safety data from DrugBank (DB00843) to populate original_moa, key_warnings, and contraindications
Re-query Singapore HSA under Donepezil and known brand names to determine actual market status
Re-generate the Evidence Pack with the corrected drug entry before proceeding to formal evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.